151 related articles for article (PubMed ID: 24675130)
21. Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta.
Balkefors V; Mattsson E; Pernow Y; Sääf M
Physiother Res Int; 2013 Dec; 18(4):203-11. PubMed ID: 23281201
[TBL] [Abstract][Full Text] [Related]
22. Osteogenesis imperfecta in childhood: prognosis for walking.
Engelbert RH; Uiterwaal CS; Gulmans VA; Pruijs H; Helders PJ
J Pediatr; 2000 Sep; 137(3):397-402. PubMed ID: 10969267
[TBL] [Abstract][Full Text] [Related]
23. Multidisciplinary Treatment of Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity.
Montpetit K; Palomo T; Glorieux FH; Fassier F; Rauch F
Arch Phys Med Rehabil; 2015 Oct; 96(10):1834-9. PubMed ID: 26140741
[TBL] [Abstract][Full Text] [Related]
24. [Osteogenesis imperfecta--upper limb in osteogenesis imperfecta].
Sułko J
Chir Narzadow Ruchu Ortop Pol; 2004; 69(6):399-402. PubMed ID: 15913026
[TBL] [Abstract][Full Text] [Related]
25. Osteogenesis imperfecta in childhood: impairment and disability--a follow-up study.
Engelbert RH; Beemer FA; van der Graaf Y; Helders PJ
Arch Phys Med Rehabil; 1999 Aug; 80(8):896-903. PubMed ID: 10453765
[TBL] [Abstract][Full Text] [Related]
26. Ankle strength and functional limitations in children and adolescents with type I osteogenesis imperfecta.
Caudill A; Flanagan A; Hassani S; Graf A; Bajorunaite R; Harris G; Smith P
Pediatr Phys Ther; 2010; 22(3):288-95. PubMed ID: 20699778
[TBL] [Abstract][Full Text] [Related]
27. [Osteogenesis imperfecta. Clinical, functional and multidisciplinary evaluation of 65 patients].
Fano V; Rodríguez Celin M; Del Pino M; Buceta S; Obregón MG; Primomo C; García H; Miscione H; Lejarraga H
An Pediatr (Barc); 2010 May; 72(5):324-30. PubMed ID: 20378435
[TBL] [Abstract][Full Text] [Related]
28. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.
Wekre LL; Eriksen EF; Falch JA
Arch Osteoporos; 2011; 6(1):31-8. PubMed ID: 22207876
[TBL] [Abstract][Full Text] [Related]
29. Results of a prospective pilot trial on mobility after whole body vibration in children and adolescents with osteogenesis imperfecta.
Semler O; Fricke O; Vezyroglou K; Stark C; Stabrey A; Schoenau E
Clin Rehabil; 2008 May; 22(5):387-94. PubMed ID: 18441035
[TBL] [Abstract][Full Text] [Related]
30. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
31. The clinical features of osteogenesis imperfecta in Vietnam.
Binh HD; Maasalu K; Dung VC; Ngoc CT; Hung TT; Nam TV; Nhan LN; Prans E; Reimann E; Zhytnik L; Kõks S; Märtson A
Int Orthop; 2017 Jan; 41(1):21-29. PubMed ID: 27807717
[TBL] [Abstract][Full Text] [Related]
32. The interaction between Sillence type and BMD in osteogenesis imperfecta.
Kok DJ; Uiterwaal CS; Van Dongen AJ; Kramer PP; Pruijs HE; Engelbert RH; Verbout AJ; Schweitzer DH; Sakkers RJ
Calcif Tissue Int; 2003 Nov; 73(5):441-5. PubMed ID: 12958692
[TBL] [Abstract][Full Text] [Related]
33. Macroscopic anisotropic bone material properties in children with severe osteogenesis imperfecta.
Albert C; Jameson J; Tarima S; Smith P; Harris G
J Biomech; 2017 Nov; 64():103-111. PubMed ID: 28988680
[TBL] [Abstract][Full Text] [Related]
34. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.
Glorieux FH; Ward LM; Rauch F; Lalic L; Roughley PJ; Travers R
J Bone Miner Res; 2002 Jan; 17(1):30-8. PubMed ID: 11771667
[TBL] [Abstract][Full Text] [Related]
35. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
36. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Aström E; Magnusson P; Eksborg S; Söderhäll S
Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
[TBL] [Abstract][Full Text] [Related]
37. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
[TBL] [Abstract][Full Text] [Related]
38. Osteogenesis imperfecta.
Bhadada SK; Santosh R; Bhansali A; Upreti V; Dutta P
J Assoc Physicians India; 2009 Jan; 57():33-6. PubMed ID: 19753756
[TBL] [Abstract][Full Text] [Related]
39. Activities and participation in young adults with osteogenesis imperfecta.
Montpetit K; Dahan-Oliel N; Ruck-Gibis J; Fassier F; Rauch F; Glorieux F
J Pediatr Rehabil Med; 2011; 4(1):13-22. PubMed ID: 21757806
[TBL] [Abstract][Full Text] [Related]
40. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
